Ironwood Pharmaceuticals Inc
$ 3.73
6.57%
03 Dec - close price
- Market Cap 606,791,000 USD
- Current Price $ 3.73
- High / Low $ 3.77 / 3.40
- Stock P/E 19.63
- Book Value -1.62
- EPS 0.19
- Next Earning Report 2026-02-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.23 %
- ROE -5.75 %
- 52 Week High 5.13
- 52 Week Low 0.53
About
Ironwood Pharmaceuticals, Inc. is a prominent biotechnology firm headquartered in Boston, Massachusetts, specializing in the development and commercialization of innovative gastroenterological therapies. The company has a strong market presence driven by its flagship product, Linzess (linaclotide), and a robust pipeline aimed at addressing significant unmet medical needs in gastrointestinal disorders. Ironwood's strategic emphasis on research, development, and partnerships enhances its therapeutic offerings and positions it for sustainable growth, promising substantial long-term value for institutional investors while ultimately improving patient outcomes.
Analyst Target Price
$2.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-13 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-15 | 2023-11-09 | 2023-08-08 | 2023-05-04 | 2023-02-16 |
| Reported EPS | 0.24 | 0.14 | -0.14 | 0.02 | 0.02 | -0.0054 | -0.02 | -0.01 | 0.09 | 0.31 | 0.25 | 0.27 |
| Estimated EPS | 0.105 | 0.03 | 0.2 | 0.0775 | 0.08 | 0.15 | 0.19 | 0.21 | 0.16 | 0.25 | 0.24 | 0.27 |
| Surprise | 0.135 | 0.11 | -0.34 | -0.0575 | -0.06 | -0.1554 | -0.21 | -0.22 | -0.07 | 0.06 | 0.01 | 0 |
| Surprise Percentage | 128.5714% | 366.6667% | -170% | -74.1935% | -75% | -103.6% | -110.5263% | -104.7619% | -43.75% | 24% | 4.1667% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.1101 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IRWD
2025-10-14 08:07:35
Inspire Investing LLC significantly increased its stake in Ironwood Pharmaceuticals (NASDAQ:IRWD) by 138.3% in the second quarter, bringing its total holdings to 552,420 shares. Other institutional investors also raised their positions in the company, which saw its stock decline by 6.6% but reported strong quarterly earnings that exceeded expectations. Ironwood Pharmaceuticals, with a market capitalization of $240.40 million, focuses on developing and commercializing gastrointestinal products.
2025-10-08 00:00:00
Zacks Research has upgraded Ironwood Pharmaceuticals (NASDAQ:IRWD) to a "strong-buy" rating due to increased confidence in the company's stock. This upgrade follows Ironwood Pharmaceuticals' strong financial performance, significantly surpassing analysts' earnings and revenue expectations. Institutional investors are also actively increasing their holdings in the company, indicating growing market interest.
2025-09-15 00:00:00
Several Boston-area biotechs are actively seeking "strategic alternatives," such as acquisitions or asset sales, in 2025. Ironwood Pharmaceuticals Inc., for instance, has engaged Goldman Sachs & Co. LLC to explore potential deals. The article suggests that these companies are still on the lookout for buyers or collaborators.
2025-08-07 11:32:00
IRONWOOD PHARMACEUTICALS (IRWD) reported strong quarterly earnings, beating analyst estimates for both earnings per share and revenue. The article details recent insider trading activity, showing more sales than purchases, and provides an overview of hedge fund adjustments to their IRWD holdings. Additionally, it lists recent price targets from several analysts, with a median target of $1.0.
2024-01-30 06:00:00
COUR Pharmaceuticals has secured $105 million in Series A financing, co-led by Lumira Ventures and Alpha Wave Ventures, with participation from major pharmaceutical companies and investment funds. These funds will advance COUR's Myasthenia Gravis and Type 1 Diabetes product candidates into Phase 2a clinical trials and support other pipeline opportunities. The investment highlights confidence in COUR's proprietary antigen-specific immune tolerance platform for treating autoimmune and inflammatory diseases.
2017-01-26 06:01:00
The FDA has approved a new 72 mcg dose of LINZESS (linaclotide) for the treatment of chronic idiopathic constipation (CIC) in adult patients, providing physicians with more dosing flexibility. This new dose is expected to be available in the first quarter of 2017, complementing the existing 145 mcg dose for CIC and 290 mcg dose for IBS-C. The approval is based on a Phase III clinical trial demonstrating statistically significant improvement in bowel movements compared to placebo.
